151 related articles for article (PubMed ID: 36124576)
1. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
Yilmaz D; Tuzer M; Unlu MB
Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
[TBL] [Abstract][Full Text] [Related]
2. Role of hypoxia-activated prodrugs in combination with radiation therapy: An
Meaney C; Powathil GG; Yaromina A; Dubois LJ; Lambin P; Kohandel M
Math Biosci Eng; 2019 Jul; 16(6):6257-6273. PubMed ID: 31698561
[TBL] [Abstract][Full Text] [Related]
3. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
Lindsay D; Garvey CM; Mumenthaler SM; Foo J
PLoS Comput Biol; 2016 Aug; 12(8):e1005077. PubMed ID: 27560187
[TBL] [Abstract][Full Text] [Related]
4. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
[TBL] [Abstract][Full Text] [Related]
5. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
Phillips RM
Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
[TBL] [Abstract][Full Text] [Related]
6. Precise gliomas therapy: Hypoxia-activated prodrugs sensitized by nano-photosensitizers.
Zhang H; Shi C; Han F; Li M; Ma H; Sui R; Long S; Sun W; Du J; Fan J; Piao H; Peng X
Biomaterials; 2022 Oct; 289():121770. PubMed ID: 36075142
[TBL] [Abstract][Full Text] [Related]
7. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.
Su MX; Zhang LL; Huang ZJ; Shi JJ; Lu JJ
Curr Drug Targets; 2019; 20(6):668-678. PubMed ID: 30468124
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.
Mao X; McManaway S; Jaiswal JK; Hong CR; Wilson WR; Hicks KO
Cancer Biol Ther; 2019; 20(9):1258-1269. PubMed ID: 31131698
[TBL] [Abstract][Full Text] [Related]
9. Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
Smith PJ; McKeown SR; Patterson LH
IUBMB Life; 2023 Jan; 75(1):40-54. PubMed ID: 35499745
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 - 2021.
Anduran E; Dubois LJ; Lambin P; Winum JY
Expert Opin Ther Pat; 2022 Jan; 32(1):1-12. PubMed ID: 34241566
[TBL] [Abstract][Full Text] [Related]
11. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
Jardim-Perassi BV; Mu W; Huang S; Tomaszewski MR; Poleszczuk J; Abdalah MA; Budzevich MM; Dominguez-Viqueira W; Reed DR; Bui MM; Johnson JO; Martinez GV; Gillies RJ
Theranostics; 2021; 11(11):5313-5329. PubMed ID: 33859749
[No Abstract] [Full Text] [Related]
12. Targeting and Treatment of Tumor Hypoxia by Newly Designed Prodrug Possessing High Permeability in Solid Tumors.
Ikeda Y; Hisano H; Nishikawa Y; Nagasaki Y
Mol Pharm; 2016 Jul; 13(7):2283-9. PubMed ID: 27187083
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
Liang D; Miller GH; Tranmer GK
Curr Med Chem; 2015; 22(37):4313-25. PubMed ID: 26487420
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.
Ghedira D; Voissière A; Peyrode C; Kraiem J; Gerard Y; Maubert E; Vivier M; Miot-Noirault E; Chezal JM; Farhat F; Weber V
Eur J Med Chem; 2018 Oct; 158():51-67. PubMed ID: 30199705
[TBL] [Abstract][Full Text] [Related]
15. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy.
Li Y; Zhao L; Li XF
Front Oncol; 2021; 11():700407. PubMed ID: 34395270
[TBL] [Abstract][Full Text] [Related]
16. Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape.
Hamis S; Kohandel M; Dubois LJ; Yaromina A; Lambin P; Powathil GG
PLoS Comput Biol; 2020 Aug; 16(8):e1008041. PubMed ID: 32745136
[TBL] [Abstract][Full Text] [Related]
17. A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs.
Sun Z; Zhang H; Wu J; Gao F; Zhang C; Hu X; Liu Q; Wei Y; Zhuang J; Huang X
Mol Pharm; 2020 Jun; 17(6):2072-2082. PubMed ID: 32352301
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
Denny WA
Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
[TBL] [Abstract][Full Text] [Related]
19. In silico analysis of hypoxia activated prodrugs in combination with anti angiogenic therapy through nanocell delivery.
Meaney C; Rhebergen S; Kohandel M
PLoS Comput Biol; 2020 May; 16(5):e1007926. PubMed ID: 32463836
[TBL] [Abstract][Full Text] [Related]
20. Prospects for hypoxia-based drug delivery platforms for the elimination of advanced metastatic tumors: From 3D modeling to clinical concepts.
Shahpouri M; Adili-Aghdam MA; Mahmudi H; Jaymand M; Amoozgar Z; Akbari M; Hamblin MR; Jahanban-Esfahlan R
J Control Release; 2023 Jan; 353():1002-1022. PubMed ID: 36516901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
